Catalyst

Slingshot members are tracking this event:

Phase 2 data from Biogen's (BIIB) BAN2401 in Alzheimer’s disease due 2H 2018

Source Link:
http://newsroom.biogen.com/press-release/adaptive-phase-ii-study-ban2401-early-alzheimers-disease-continues-toward-18-month-end

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BIIB Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jul 25, 2018
Occurred Source:
http://media.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-detailed-results-phase-ii-clinical
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Ban2401, Alzheimer's Disease
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.